Author: Katrina Megget

Opinion on the new drug pricing scheme and value-based assessment remians negative after a PharmaTimes snap poll showed just 13% considered the PPRS good for patients and 61% believing VBA will not improve access to medicines.

The new Pharmaceutical Pricing Regulatory Scheme is unlikely to deliver the benefit to patients that the government and ABPI have promised, a leading patient advocate says.

The UK Government believes the new pharmaceutical drug pricing scheme will increase the uptake and adoption of innovative medicines.

Shire and Lundbeck have claimed the top title of marketing companies of the year in the prestigious PharmaTimes Marketer of the Year competition, the results of which were announced in London last night.

Sales and profits at AstraZeneca have slumped dramatically in the third quarter as generic competition continues to batter the Anglo-Swedish drugmaker.